Four-Time Honoree! Sinogen Pharmaceutical Again Named to Guangzhou's "Future Unicorn" List in 2025

The compilation of the 2025 "Guangzhou Unicorn Innovative Enterprises List" was conducted under the guidance of the Guangzhou Municipal Science and Technology Bureau. It selected a total of 210 high-growth innovative enterprises, including 105 "Future Unicorn" companies. The list focuses on hard-tech sectors such as biomedicine, artificial intelligence, and advanced manufacturing, with core evaluation criteria including technological barriers, growth potential, and industrial driving effects. It serves as a key indicator of the innovation and entrepreneurial vitality in the Greater Bay Area. Sinogen Pharma's selection for four consecutive years highlights the industry and regulatory authorities' sustained recognition of its innovative capabilities and development prospects.

Founded by four national-level experts specially appointed as high-level talents, Sinogen Pharma is dedicated to the field of innovative biological anti-tumor drugs. Its core competitiveness lies in its globally leading oncolytic bacteria technology platform. Its independently developed First-in-class oncolytic bacteria drug, SalMet-Vec® (SGN1 Injection), is the world's first precision-targeted oncolytic bacterial vector genetically engineered biological product to enter the clinical trial stage. It achieves broad-spectrum anti-tumor effects by depriving tumors of essential amino acids necessary for their growth. Currently, this product has obtained FDA Orphan Drug Designation for treating osteosarcoma, liver cancer, small cell lung cancer, pancreatic cancer, and nasopharyngeal carcinoma, as well as Fast Track Designation for metastatic osteosarcoma and recurrent/metastatic head and neck squamous cell carcinoma. It has also been included in the Key Varieties Service List of the NMPA Drug Evaluation and Inspection Greater Bay Area Sub-center. International multi-center Phase I/IIa clinical trials are being conducted simultaneously in China, the United States, and Taiwan, China, demonstrating significant clinical value and global potential.

We believe that inclusion on this list is both an honor and a motivation. In the future, the company will continue to focus on the treatment of malignant tumors and rare diseases, deepen industry-university-research collaborative innovation, accelerate the progress of international multi-center clinical trials, empower the healthcare sector with breakthrough biopharmaceutical technologies, and contribute more innovative strength to Guangzhou's efforts in building a modern industrial system and developing new quality productive forces.